Wednesday, September 07, 2016

SilverCrest (TSXV: $SIL.V) Announces Further Drill Hole Results From Las Chispas Project; Confirms Discovery of the Unmined Extension of William Tell Vein


SilverCrest (TSXV: $SIL.V) Announces Further Drill Hole Results From Las Chispas Project; Confirms Discovery of the Unmined Extension of William Tell Vein
                      


VANCOUVER, BC – September 07, 2016 - (Investorideas.com Newswire) SilverCrest Metals Inc.  (TSXV: $SIL.V) (“SilverCrest” or the “Company”) is pleased to announce additional drill hole results from the William Tell Vein within its Las Chispas Project located in Sonora State, Mexico. The Las Chispas Project is in a historic silver-gold mining district which presently hosts two nearby precious metal producers. Historic information indicates that of the fourteen historically reported veins at Las Chispas Project, only three veins, the Las Chispas, William Tell and Babicanora, had documented production, which occurred between 1880 and 1930. SilverCrest’s initial focus is on these three veins. To the Company’s knowledge, these three past-producing veins have not been intercepted by drilling prior to the Company's recently completed initial Phase I drilling campaign. For more information, please refer to our website at www.silvercrestmetals.com.

The William Tell Vein is approximately parallel to the Las Chispas Vein and about 120 metres apart at its midpoint. The William Tell Vein’s historical workings appear to advance on strike to a cross cutting fault and then terminate. This fault also cross cuts the Las Chispas Vein beyond which higher grades and continuity are found as previously reported (see news release dated August 2, 2016). The Company believes this fault bound corridor, in both the William Tell and Las Chispas Veins, may be a mineralizing control for a potential high grade zone in both of the vein systems. Four of the seven William Tell drill hole intersections located within the potential high grade corridor display grade continuity greater than 400 grams per tonne (“gpt”) silver equivalent* (“AgEq”) over estimated true widths of 0.8 to 1.5 metres. Applying a 50 metre radius influence to the four drill hole intercepts, the area covers approximately 300 metres of strike (see attached figure). No historical workings were intercepted in the seven William Tell Vein drill holes.



Two previously unmapped veins were intercepted in drill holes LC16-13 and LC16-16 at the William Tell Vein which reported grades of 888 gpt AgEq* and 723 gpt AgEq* over estimated true widths of 0.9 metres and 0.8 metres, respectively (see table below). These intercepts are new vein discoveries and are interpreted to be in the footwall and hanging wall, respectively. 

Dunham Craig, P.Geo., Interim CEO commented, “While we suspected the William Tell Vein would extend to the south, we are very pleased to see this discovery in an area where we did not know what the vein mineralization, location or geometry would be. The high grade continuity in four of the drill holes within the potentially mineralized corridor is very encouraging and we are eager to begin a Phase 2 drilling program as soon as possible to further delineate the strike extension and depth. In addition, the discovery of two new vein intercepts grading above 700 gpt AgEq*, combined with all of the results received to date from drilling and underground channel sampling, reiterate a possible discovery of a district-wide area play. The crew in Mexico continues to gain further access within the estimated 11.5 kilometres of historic underground workings in both the Las Chispas area and Babicanora area for mapping, sampling and future drilling program design. We expect to report on further drill results and underground activities over the coming weeks. ” 

The most significant William Tell Vein core drilling results for this release are 1.5 metres wide grading 2.03 gpt gold (“Au”) and 683 gpt silver (“Ag”), or 835 gpt AgEq* (see attached figure) including 0.75  metres grading 3.8 gpt Au and 1,102 gpt Ag or 1,388 gpt AgEq* in hole LC16-03. The following table summarizes the most significant drill assay results (uncut) for the William Tell vein and the previously unidentified veins;






William Tell Drill Hole Intercepts within Potentially High Grade Corridor > 150 gpt AgEq
Hole No.
From (m)
To (m)
Drilled Thickness (m)
Est. True Thickness (m)** 
Au gpt
Ag gpt
AgEq* gpt 
LC16-03
172
176
4
1.5
2.03
683
835
includes
173
175
2
0.8
3.81
1,102
1,388
LC16-12
118
119
1
0.9
2.40
229
409
LC16-13
168
172
4
3.2
1.08
141
222
includes
168
169
1
0.8
3.58
249
517
Includes
171
172
1
0.8
0.23
249
266
LC16-15
197.5
199
1.5
1.3
1.94
352
497
New Identified Vein Intercepts adjacent to the William Tell Vein
LC16-13
180
181
1
0.8
4.79
364
723
LC16-16
93
94
1
0.9
6.57
395
888
William Tell Drill Hole Intercepts < 150 gpt AgEq
LC16-02
94
95
1
0.5
0.97
20
94
LC16-04
201
205
4
1.7
0.04
69
72
LC16-16
270
272
2
1.8
0.01
39
40
Note: all numbers are rounded.
*AgEq based on 75 (Ag):1 (Au) and 100% metallurgical recovery.
** All holes were drilled at angles to mineralization; true thickness is estimated based on geometry of the vein model.
                             
All assays were completed by ALS Chemex with sample preparation in Hermosillo, Mexico and assayed in North Vancouver, BC.

Gold grades are reported from fire assay, and silver grades >100 gpt are reported from aqua regia digestion with ICP-AES finish.

As previously announced, the Company has also drilled three holes (LV-16-01, LV-16-02 and LV-16-03) in the La Victoria area, a separate mineralized showing, located 800 metres southwest of the Babicanora vein. Results from these holes have shown mineralization but with relatively low values.  Future drilling for the La Victoria area will be undertaken to define the zonation of grade closer to surface and at depth.

Based on the favorable results of the Phase I surface drill program, the Company is planning a Phase II surface and underground drill program for the fall of 2016.Timing of the underground drilling program depends on the receipt of the permit application. The program will focus on the delineation of a potential bulk sample and infill drilling in preparation for a maiden resource estimate at the Las Chispas project.

The Qualified Person under National Instrument 43-101 Standards of Disclosure for Mineral Projects for this news release is James Barr, P.Geo, who is independent of SilverCrest and has approved its contents.


ABOUT SilverCrest Metals INC.
SilverCrest is a Canadian precious metals exploration company headquartered in Vancouver, BC, that is focused on new discoveries, value-added acquisitions and targeting production in Mexico’s historic precious metal districts. The Company is led by a proven management team in all aspects of the precious metal mining sector, including the pioneering of a responsible “phased approach” business model taking projects through discovery, finance, on time and on budget construction, and production with subsequent increased value to shareholders.  

FORWARD-LOOKING STATEMENTS
This news release contains “forward-looking statements” within the meaning of Canadian securities legislation. These include, without limitation, statements with respect to: the strategic plans, timing and expectations for the Company’s exploration, rehabilitation and drilling programs of the Las Chispas Project; information with respect to high grade areas and size of veins projected from underground sampling results; and the accessibility of future mining at the Las Chispas Project. Such forward‑looking statements or information are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: the conditions in general economic and financial markets; availability of skilled labour; timing and amount of expenditures related to rehabilitation and drilling programs; and effects of regulation by governmental agencies. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors including: the timing and content of work programs; results of exploration activities; the interpretation of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project cost overruns or unanticipated costs and expenses; and general market and industry conditions. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Dunham L. Craig, P.Geo., Director
Interim CEO
SilverCrest Metals Inc.

Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:
SilverCrest Metals Inc.
Fred Cooper, Investor Relations
Telephone: +1 (604) 694-1730
Fax: +1 (604) 694-1761
Toll Free: 1-866-691-1730 (Canada & USA)
570 Granville Street, Suite 501, Vancouver, British Columbia V6C 3P1


More info on SIL.V at Investorideas.com: http://www.investorideas.com/CO/SILV/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp. Disclosure:Investorideas.com is compensated by SilverCrest Metals Inc for annual news publishing effective January 2016.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.




Live Tech Demo of the Guardian Patch ($GOPH) Location Tracking Technology to Take Place on September 14, 2016

Live Tech Demo of the Guardian Patch ($GOPH) Location Tracking Technology to Take Place on September 14, 2016



SAN DIEGO, CA - September 7, 2016 (Investorideas.com Newswire) Gopher Protocol Inc. (OTCQB:GOPH) ("Gopher" and the "Company"), a development-stage Company which specializes in the development of real-time, heuristic-based mobile technologies, and its partner, Guardian Patch LLC, announce they have scheduled a live demonstration of their Guardian Patch prototype. The Guardian Patch prototype demo will take place on Tuesday, September 14, 2016 between 10:00 a.m. and 11:00 a.m. Pacific Time.

When:
September 14, 2016 10:00 a.m. - 11:00 a.m. Pacific Time

Where:
Online through the Guardian Patch mobile application, which may be downloaded for free at the Apple Store under the name "Guardian Patch" and on Google Play under the name "Guardian Tracking Device".

What:
Live Demo of the Guardian Patch Location Technology - A stick-on tracking device that is designed to protect people's valuables.

By downloading the Guardian Patch mobile application, users can watch live demonstrations of vehicles utilizing the Patch in the San Diego, CA region.

Guardian Patch download on iTunes

Guardian Patch download on Android

As previously announced, the test results of the Company's GOPHERINSIGHT™ technology proved range coverage of approximately 30 square miles in areas without tall buildings. The GOPHERINSIGHT™ prototypes have been shipped to the Company's offices in San Diego, CA for further testing within a larger and more densely populated urban area.

How it works:
The Guardian Patch (the "Patch"), potentially arriving in consumer markets in 2017, is a unique location technology that works with or without GPS. The Patch is a "stick-on" device that provides its users with the capability to protect and track objects, a loved-one or even a pet, through a mobile application. Download the Patch app, register your patch, and track anything that you own on your mobile device or on our designated website. Register the Patches of your family members and friends to receive alerts in the event of an emergency. Peel the Patch off and the Patch acts as a beacon, sending out a signal and notifying anyone who has registered the user's Patch. http://www.guardianpatch.com/




Product lifecycle management is the process of managing the entire lifecycle of a product from inception, through engineering design and manufacture, to service and disposal of manufactured products. The lifecycle of a product will generally include: Phase 1: Conceive - imagine, specify, plan, innovate; Phase 2: Design - describe, define, develop, test, analyze and validate; Phase 3: Realize - manufacture, make, build, procure, produce, sell and deliver; and Phase 4: Service - use, operate, maintain, support, sustain, phase-out, retire, recycle and disposal.

The Patch is currently in Phase 2 (Design), where the detailed design and development of the product's form begins, progressing to prototype testing, through pilot release to full product launch. This step covers many engineering disciplines, including, mechanical, electrical, electronic, software (embedded, server, mobile) and domain-specific, such as communication protocol design, along with the actual creation of the product including the analysis of the components, product assembly and packaging.

In addition, the Company plans to develop a social challenge in the future which will be named "Find Patch Number One", as previously disclosed by the Company and as further described in the following YouTube video of presentation about the Patch: https://www.youtube.com/watch?v=C-aSj9TUUmw (minutes 2:03-3:58 describe the contest)



About Gopher Protocol Inc.
Gopher Protocol Inc. (OTCQB: GOPH) (“Gopher” and the "Company") (http://gopherprotocol.com/) is a development-stage company developing a real-time, heuristic-based mobile technology.  Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that will run on a server.  The system contemplates the creation of a global network.  Gopher believes this will be among the first system that is developed using a human, heuristic-based analysis engine.  Since the core of the system will be its advanced microchip technology that will be capable of being installed in any mobile device worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the microchip by providing mobile technology for computing power enhancement, advanced mobile database management/sharing and other additional mobile features.

Corporate Site: http://gopherprotocol.com


Consumer and product website for Guardian Patch: http://www.guardianpatch.com/

Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:
Danny Rittman CTO
Gopher Protocol Inc.
VM Only - 888-685-7336

Visit this company: http://gopherprotocol.com/

More info on GOPH at Investorideas.com Visit: http://www.investorideas.com/CO/GOPH/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com ( three months effective April 4, 2016- three thousand five hundred per month )

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.




Tuesday, September 06, 2016

Aethlon Medical (Nasdaq: $AEMD) Announces Upcoming September Investor And Industry Conferences

Aethlon Medical (Nasdaq: $AEMD) Announces Upcoming September Investor And Industry Conferences


SAN DIEGO - September 6, 2016 (Investorideas.com newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), announced today its upcoming conference schedule for the month of September. Aethlon management will be presenting at the following conferences and is available for one-on-one meetings at the events. Additional details, including presentation and webcast information will be announced in the future, and will be posted on the investor relations section of the Aethlon website at www.aethlonmedical.com.

September 11-13, 2016 
Rodman & Renshaw 18th Annual Global Investment Conference
 
New York, NY
 
Presentation: Tuesday, September 13, 2:10 PM ET

September 20-22, 2016 
Aegis Capital 2016 Annual Growth Conference
 
Las Vegas, NV
 
Presentation: Wednesday, September 21, 2:25 PM ET

September 26-28, 2016 
Robins Equity Research Conference
 
Portland, OR
 
Presentation: Tuesday, September 27, 1:00 PM ET

September 29-30, 2016 
3rd Annual Liquid Biopsies and Minimally-Invasive Diagnostics 2016
 
San Diego, CA
 
Presentation: Friday, September 30, 3:00 PM ET


About Aethlon Medical
Aethlon Medical (AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. Aethlon is part of the Russell Microcap® Index. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.


The Hemopurifier® in Cancer
Upwards of ninety percent of all cancer-related deaths are attributed to metastasis; the spread of cancer from a primary site of origin to other organs or areas of the body. The mechanism of how tumors metastasize to distant sites in the body has long been one of cancer's greatest mysteries. That mystery was recently solved when circulating particles known as tumor-derived exosomes were discovered to be the seeds that promote the spread and growth of cancer metastasis.

Aethlon initiated its tumor-derived exosome research at a time when the medical community believed exosomes were merely cellular debris with no biological function. Today, a therapeutic to address tumor-derived exosomes represents a significant unmet need in cancer care. Aethlon has demonstrated that the affinity mechanism of the Hemopurifier® can capture tumor-derived exosomes underlying several forms of cancer, including breast, ovarian and metastatic melanoma.

Beyond their role in metastasis, researchers have also published mounting evidence that tumor-derived exosomes contribute to tumorigenesis (the formation of cancer), cancer progression, angiogenesis (creation of blood vessels to fuel tumor growth), immune evasion, and resistance to radiation and chemotherapeutic drugs. Recent discoveries also reveal that exosomes may contribute to bacterial and viral pathogenesis, the progression of Alzheimer and Parkinson's diseases, the spread of prion proteins, and numerous inflammatory conditions.

The Hemopurifier® in Infectious Disease
Emerging pathogens pose a significant threat to mankind. Of the hundreds of viral pathogens known to be infectious to man, only a few are addressed with proven antiviral drug or vaccine therapies. Beyond the looming threat of bioterrorism, a proliferation of international travel, urban crowding and global warming is expected to accelerate the emergence of future pandemics. In response, the U.S. Department of Health and Human Services (HHS) has established an initiative to support platform technology medical countermeasures with broad-spectrum capabilities. Based on preclinical studies and human treatment experiences, the Aethlon Hemopurifier® defines this initiative.

To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."

Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats. These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection. Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919. In vitro studies of other viral threats are ongoing.

Aethlon has also demonstrated that the Hemopurifier captures the bacteria toxins lipopolysaccharide (LPS) and lipoteichoic acid (LTA). These studies were conducted under a contract with the Defense Advanced Research Projects Agency (DARPA) related to the treatment of sepsis.


About Exosome Sciences
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical (Nasdaq: AEMD), is focused on the discovery of exosomal biomarker candidates to diagnose and monitor life-threatening diseases. The proprietary Enzyme-Linked Lectin-Specific Assay (ELLSA™) serves as a platform to isolate exosomal biomarkers from a wide-range of bodily fluids. In preliminary studies, ELLSA™ demonstrated the ability to isolate exosomes from urine, which resulted in high-sensitivity detection of HIV-infection. Specific to neurological disorders, Exosome Sciences discovered TauSome™, an exosomal biomarker that may be the first non-invasive candidate to detect Chronic Traumatic Encephalopathy (CTE) in living individuals. In a study of former National Football League (NFL) players, TauSome levels were found to be significantly higher as compared to athlete control subjects who participated in non-contact sports. TauSome levels also correlated with cognitive decline based standardized tests of memory and psychomotor speed. Visit www.exosomesciences.com for additional details.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, including any products relating to the Zika virus, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2016, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:
Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc
212-986-6667
smarg@braincomm.com

Visit this Company: www.AethlonMedical.com

More info on AEMD at Investorideas.com: http://www.investorideas.com/CO/AEMD/

Sign up for the free investor news and stock alerts:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD August 11, 2016 – one month of PR. News publication and social media – two thousand five hundred  

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.